COMP <GO>
MMM vs LLY // REVENUE GROWTH (YOY)
3M Company (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MMM 6
— LLY 9
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $174.34 (-1.70%) • MKT CAP: $91.65B
revenue-growth
1.50%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 39.90% | 83.64% | -43.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | 32.36% | +0.54 | MMM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.1x | 36.4x | -18.32 | MMM | /valuation <GO> |
| Free Cash Flow Yield | 1.52% | 2.30% | -0.78 | LLY | /fcf-yield <GO> |
| Operating Margin | 18.60% | 40.21% | -21.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 13.00% | 31.90% | -18.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 1.50% | 45.51% | -44.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.70% | 0.49% | +1.21 | MMM | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.37 | 9.29 | -4.92 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | MMM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 77.9 | -19.36 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.51 | +0.40 | MMM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.2x | 26.3x | -0.05 | MMM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $91.65B | $1.33T | -$1.24T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMM REV | LLY REV | MMM GROSS % | LLY GROSS % | MMM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $24.95B | $65.18B | 39.9% | 83.0% | $1.40B | $16.81B |
| FY 2024 | $24.57B | $45.04B | 41.2% | 81.3% | $638.0M | $8.82B |
| FY 2023 | $24.61B | $34.12B | 44.0% | 79.3% | $5.57B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMM // BETA 0.91
LLY // BETA 0.51